1. Team Introduction
The neurosurgical critical care center of Department of neurosurgery, Xuanwu Hospital, Capital Medical University, was established in August 2003 with 16 beds. It is one of the earliest neurosurgical critical care centers in China. In December 2018, with the opening of the China-INI, the center expanded to 38 beds, with ward 1 located on the seventh floor of the China-INI building, and ward 2 on the fourth floor of the Surgery Building.
This highly specialized center is dedicated to caring for critically ill, neurologically impaired patients. The leading specialist is Prof. Ning Wang, and the chief is Prof. Rongcai Jiang with 2 attending physicians, Yueqiao Xu and Xin Qu, each leading a team. Totally there are 10 full-time neurosurgical critical care physician and 71 nurses.
2. Specialized Diseases
This center mainly admit patients with severe cerebrovascular disease (both ischemic and hemorrhagic, especially aneurysmal subarachnoid hemorrhage), traumatic brain injury, intracranial infection, perioperative period of complicated neurosurgeries, such as lesions at sella turcica, petroclival region, brain stem, and so on. And some are conscious-impaired patients with hydrocephalus and cranial defect who need treatment.
The management concept of this center is neuroprotection combined with multiple systemic organs support, to postpone or even avoid the secondary brain injury, and achieve better outcome. Temperature management and proper analgesia and sedation are usually applied for severely brain injured patients. They are skilled in diagnosing and accurately judging the prognosis of acute coma patients. Besides the widespread used tools in general ICU like bedside ultrasound, PICCOs, CVP, EtCO2 and hemodialysis, there are many neurological-specific instruments, like ICP (ventricular and parenchymal), TCD, EEG, NIRS, which comes as multimodality neurological monitoring for patients. Resulted from the joint effort of the NICU employees, about 11,000 neurosurgical critical and perioperative patients have been admitted since 2019.
Prof. Jiang is the leading explorer in atorvastatin treatment for CSDH since 2009 and published 27 papers focusing on CSDH in international journals to elucidate of the mechanism of atorvastatin treatment for CSDH and a serial of cases reports. He further optimized the medical therapeutic strategy by adding vitamin D or dexamethasone. He has cured more than 1200 CSDH patients in China with ≥90% efficiency just with atorvastatin or atorvastatin combined with dexamethasone but not the surgical therapy. Besides these, two post-operational relapsed CSDH patients from Australia and USA respectively were also cured by Prof. Jiang’s prescription. The therapeutic strategy based on atorvastatin and dexamethasone for CSDH has now been broadly accepted and thousands of CSDH patients have been benefited in mainland of China and Hongkong. A new potential world-wide therapeutic guideline for CSDH might emerge.
3. Training Programs
There are two neurosurgical critical care training courses every year (half a year each), each can be divided into two parts: theoretical and practical, which are merged into everyday clinical work. Nearly 100 intensive doctors or neurosurgeons who are dedicated themselves to neurosurgical critical care have already finished the courses.
Multimodal neurocritical monitoring
You can find professional doctors and experts about this center here for your further consultation
Any use of this site constitutes your agreement to the Terms and Conditions and Privacy Policy linked below.
A single copy of these materials may be reprinted for noncommercial personal use only. "China-INI," "chinaini.org" are trademarks of China International Neuroscience Institute.
© 2008-2021 China International Neuroscience Institute (China-INI). All rights reserved.